Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment
نویسندگان
چکیده
Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders include increased flux of free fatty acids (FFA), raised triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C) levels, a predominance of small, dense (atherogenic) low density lipoprotein cholesterol (LDL) particles and raised apolipoprotein (apo) B values Posprandial hyperlipidaemia may also be present. Insulin resistance (IR) appears to play an important role in the pathogenesis of dyslipidaemia in obesity, MetS and T2DM. The cornerstone of treatment of this IR-related dyslipidaemia is lifestyle changes and in diabetic patients, tight glycaemic control. In addition to these measures, recent clinical trials showed benefit with statin treatment. Nevertheless, a substantial percentage of patients treated with statins still experience vascular events. This residual vascular risk needs to be addressed. This review summarizes the effects of hypolipidaemic drug combinations (including statins with cholesterol ester protein inhibitors, niacin, fibrates or fish oil, as well as fibrate-ezetimibe combination) on the residual vascular risk in patients with obesity, MetS or T2DM.
منابع مشابه
Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD
Given evidence of increasing prevalence in developed and developing countries, as a result of obesity trends and sedentary lifestyles, the metabolic syndrome represents an increasing burden on healthcare systems. Management guidelines for dyslipidaemia have primarily focused on LDL-C reduction; however, this approach fails to sufficiently address other lipid abnormalities associated with the me...
متن کاملPrevalence and Risk Factors of Diabetes, Pre-Diabetes and Metabolic Syndrome in First-Degree Relatives of Patients with Type II Diabetes
Background & Aims: The aim of this study was to estimate the prevalence and risk factors for diabetes, pre-diabetes and metabolic syndrome in first-degree relatives(FDRs) of patients with type 2 diabetes. Methods: In a cross-sectional study between 2003 and 2005, 3228 of first-degree relatives of patients with type 2 diabetes (841 men and 2387 women) from Isfahan Endocrine and Metabolism Resear...
متن کاملPemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
Despite best evidence-based treatment including statins, residual cardiovascular risk poses a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in particular elevated triglycerides, a marker for increased triglyceride-rich lipoproteins and their remnants, is an important contributor to lipid-related residual risk, especially in insulin resistant conditions s...
متن کاملClinical implications of the metabolic syndrome.
The prevalence of the metabolic syndrome among developed countries is rising, and this is largely driven by increasing obesity rates. Central obesity plays a key role in the pathogenesis of the metabolic syndrome: it promotes inflammation, hypertension and dyslipidaemia, and leads to the development of type 2 diabetes mellitus and atherosclerosis. Clinical management should be focused on multif...
متن کاملComparison of Serum Level and IL-18 Gene Expression and Reactive Protein in Patients with Type 2 Diabetes with Metabolic Syndrome and Healthy People
Introduction: Metabolic syndrome is a common clinical anomaly, with an increased risk of developing type 2 diabetes and cardiovascular risk factors. Increased inflammatory mediators, such as reactive protein,as well as the inflammatory cytokines can be associated with the incidence and progression of metaboli syndrome and type 2 diabetes. Materials & Methods: This study was performed on 35 m...
متن کامل